SAE stands for Serious Adverse Event in clinical research. It refers to any untoward medical occurrence that results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, or results in persistent or significant disability/incapacity.
SAEs are a crucial aspect of drug safety monitoring during clinical trials. They must be promptly reported to regulatory authorities and ethics committees, and may lead to changes in study protocols or even the termination of a clinical trial if the risk to participants is deemed too high.
SAEs are critical indicators of a drug’s safety profile during clinical trials. They help researchers and regulatory bodies assess the potential risks associated with investigational treatments, ensuring that participant safety remains the top priority throughout the study.
The identification and proper reporting of SAEs can significantly impact the course of a clinical trial and the eventual approval of a new drug. Timely recognition and management of SAEs allow for appropriate interventions, protocol modifications, and informed decision-making regarding the continuation or termination of a study.
Europe’s clinical trials market is entering a more practical phase in its approach to competitiveness. With the Clinical Trials Regulation…
The Axcellant team recently attended the International Conference on Nuclear Cardiology (ICNC) in Berlin – one of the most important…
Axcellant is pleased to announce the formation of its Advisory Board - a group of distinguished experts in clinical science,…
Copyright @ 2026 Axcellant